Currently seeking Ph.D. students
Jean Patterson, Ph.D.
Department of Microbiology
Immunology & Molecular Genetics
Since the anthrax attacks in 2001, the U.S. government has been committed to developing countermeasures to potential biological weapons, now referred to as select agents. Texas Biomed has had a BSL4 maximum containment laboratory since 2000. Dr. Patterson’s laboratory has worked on the development of countermeasures against many select agents. Her group works to develop therapies and vaccines against naturally occurring pathogens that can cause sporadic but lethal outbreaks. She has helped develop three vaccines against Ebola, one with Emory University and one with Crucell pharmaceuticals and one with Bavarian Nordic, all are undergoing further studies.
Areas of Research: Virol Pathogenesis and Vaccine Development Research
Associated Diseases: Ebola, Zika viruses
Techniques Used: Viral culture, molecular detection techniques and immunology assessments
Research & Grants
Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brister JR, Bukreyev AA, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Hensley LE, Honko AN, Jahrling PB, Johnson KM, Kobinger G, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Saphire EO, Smither SJ, Swanepoel R, Towner JS, van der Groen G, Volchkov VE, Wahl-Jensen V, Warren TK, Weidmann M, Nichol ST. Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol. 2013 Jan;158(1):301-11.
Salvador B, Sexton NR, Carrion R Jr, Nunneley J, Patterson JL, Steffen I, Lu K, Muench MO, Lembo D, Simmons G. Filoviruses utilize glycosaminoglycans for their attachment to target cells.J Virol. 2013 Mar;87(6):3295-304.
Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, Green CE, Iyer LV, Dilks HH, Davey RA, Kolokoltsov AA, Carrion R Jr, Patterson JL, Bavari S, Panchal RG, Warren TK, Wells JB, Moos WH, Burke RL, Tanga MJ. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One. 2013;8(4):e60579.
Alonso JA, Patterson JL. Sequence variability in viral genome non-coding regions likely contribute to observed differences in viral replication amongst MARV strains. Virology. 2013 May 25;440(1):51-63.
Olejnik J, Alonso J, Schmidt KM, Yan Z, Wang W, Marzi A, Ebihara H, Yang J, Patterson JL, Ryabchikova E, Mühlberger E. Ebola virus does not block apoptotic signaling pathways. J Virol. 2013 May;87(10):5384-96.